Dr Kaklamani talks to ecancertv at SABCS 2015 about results from the ongoing, prospective Trial Assigning Individualized Options for Treatment (TAILORx) involving more than 10,000 women with estrogen receptor (ER)-positive, HER2-negative, axillary node-negative breast cancer.
TAILORx has been designed to demonstrate whether the Oncotype DX can be used to correctly identify women who may not need chemotherapy and could safely be given endocrine treatment alone.
In the study, patients with a low Oncotype DX recurrence score (RS) were assigned to endocrine therapy alone and with those with a high RS assigned to chemoendocrine therapy. Women with an intermediate (11-25) RS were treated with chemoendocrine therapy or endocrine therapy alone and results of that study arm are expected in the future.
Dr Kaklamani discusses the data from the low risk group who received endocrine treatment alone. Five-year rates for distant relapse-free interval, the relapse-free interval, invasive disease free survival, and overall survival were a respective 99.2%, 98.5%, 93.7%, and 98.2%.
The findings show that despite meeting guidelines for recommending or at least considering adjuvant chemotherapy based on classical clinical and pathological features, the risk of recurrence was very low at 5 years. This population of women patients may be very effectively treated with endocrine therapy alone without chemotherapy.
